Table 3 Treatment and prognosis of patients with RSV-related encephalopathy
Findings | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
|---|---|---|---|---|---|---|---|---|
Glucocorticoids | - | - | + | + | + | + | + | + |
IG | + | + | + | + | - | + | - | + |
Antiviral drugs | + | + | - | + | - | - | + | + |
Sedatives and anticonvulsive drugs | - | - | midazolam | midazolam | midazolam, clonazepam, levetiracetam, diazepam | midazolam, phenobarbital, levetiracetam, diazepam, propofol | phenobarbital, midazolam, diazepam | phenobarbital, propofol, diazepam, levetiracetam |
Concentrated sodium chloride | + | - | + | + | - | + | - | - |
Mannitol | + | - | + | + | + | + | + | + |
Invasive ventilation time (d) | 5 | 0 | 7 | 4 | 6 | 7 | 0 | 12 |
Vital status and GCS score at discharge | Death | 15 | 15 | 15 | 14 | 14 | 15 | 15 |
Follow-up time (m) | - | 6.50 | 4.67 | 4.58 | 0.50 | 0.50 | 6.50 | 4.50 |
POPC score at follow-up | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |